Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN SODIUM IN PLASTIC CONTAINER versus LIQUAEMIN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN SODIUM IN PLASTIC CONTAINER versus LIQUAEMIN SODIUM.
HEPARIN SODIUM IN PLASTIC CONTAINER vs LIQUAEMIN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin binds to antithrombin III, inducing conformational change that accelerates its inhibition of thrombin (factor IIa), factor Xa, and other coagulation factors (IXa, XIa, XIIa).
Heparin binds to antithrombin III, accelerating the inactivation of thrombin and factor Xa, thereby inhibiting coagulation cascade.
Initial IV bolus of 80 units/kg followed by continuous IV infusion of 18 units/kg/hour; dose adjusted based on aPTT. Typical infusion range 10-30 units/kg/hour. Subcutaneous route: 5000 units every 8-12 hours for prophylaxis.
Initial adult dose: 5,000 units IV bolus, followed by continuous IV infusion at 1,000–2,000 units/hour; or 10,000–20,000 units subcutaneously every 12 hours. Dose adjusted based on aPTT.
None Documented
None Documented
30-150 minutes (dose-dependent: 0.5-1.5 h at low doses, up to 2.5 h at high doses). Prolonged in hepatic or renal impairment.
Mean 1.5 hours (range 1-2 hours) after IV administration; increases with dose (e.g., 25,000 U IV: ~2.5 h). Clinical context: nonlinear pharmacokinetics; half-life prolonged in hepatic or renal impairment.
Renal (predominantly), with minor biliary/fecal elimination. Clearance is dose- and concentration-dependent due to saturable binding.
Primarily renal (heparin is metabolized and excreted as uroheparin and other metabolites; up to 50% of administered dose appears in urine as unchanged heparin, but clearance is dose-dependent and nonlinear).
Category A/B
Category C
Anticoagulant
Anticoagulant